Neuroprotective effects of Yiqihuoxue calm wind capsule on ischemic stroke in rats.
10.1016/S1875-5364(17)30107-3
- Author:
Jun-Xia ZHANG
1
;
Jiao-Mei GUO
2
;
Hong-Jun LIN
2
;
Ting-Ting ZHANG
2
;
Zhen-Guo LI
2
;
Ji-Chun ZHOU
2
;
Zhen-Zhong ZHANG
3
,
4
Author Information
1. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450001, China; Department of Pharmacology, Henan Provincial Institute of Food and Drug Control, Zhengzhou 450003, China.
2. Department of Pharmacology, Henan Provincial Institute of Food and Drug Control, Zhengzhou 450003, China.
3. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450001, China; Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases of Henan Province, Zhengzhou 450001, China. Electronic address: zhenzhongz@
4. com.
- Publication Type:Journal Article
- Keywords:
Ischemic stroke;
Middle cerebral artery occlusion;
Nitric oxide;
Oxidative stress;
Platelet;
Yiqihuoxue calm wind capsule
- MeSH:
Animals;
Brain Ischemia;
drug therapy;
genetics;
metabolism;
Humans;
Male;
Malondialdehyde;
metabolism;
Neuroprotective Agents;
administration & dosage;
Oxidative Stress;
drug effects;
Rats;
Rats, Sprague-Dawley;
Stroke;
drug therapy;
genetics;
metabolism;
Superoxide Dismutase;
metabolism
- From:
Chinese Journal of Natural Medicines (English Ed.)
2017;15(10):758-765
- CountryChina
- Language:English
-
Abstract:
Stroke remains the third leading cause of death and of adult disability worldwide. Vascular occlusion, followed by ischemic cascade, leads to irreversible tissue injury. Recombinant tissue plasminogen activator is the only FDA approved drug for the current treatment of acute ischemic stroke. However, traditional Chinese medicine has a long history and rich clinical experience in the treatment and rehabilitation of ischemic stroke. Using a classical middle cerebral artery occlusion (MCAO) stroke model, we tested the effectiveness of Yiqihuoxue calm wind (YCW) capsule on neurological function, gross pathology and oxidative stress status in MCAO rats. YCW capsule (3.36 and 6.72 g·kg of crude drug) could significantly lower Longa's score and superoxide dismutase (SOD) level, together with less necrotic cells and infarcted area. In addition to elevated MDA and downregulated iNOS expression, YCW capsule exhibited its neuroprotective effects via free radical scavenging and NO inhibition.
